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Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent disorders 
encountered in child psychiatry and is increasingly being recognized also in adults. 
Still, controversies exist about the diagnosis both among health care practitioners and 
lay people.  
Current diagnostic criteria for psychiatric disorders are purely descriptive in nature, 
classified on the basis of empirical observations of clustering and course of symptoms 
and behaviour into clinically recognizable entities. Due to insufficient knowledge 
about their etiology, there are no objective tests that can verify a diagnosis. 
Assessment of psychiatric disorders is therefore to a large extent dependent on clinical 
knowledge and experience.  
As diagnostic criteria, research and clinical experience on ADHD are historically 
mainly based on children; clinical knowledge of ADHD in adults has so far been 
limited. Recent years’ awareness of ADHD as a lifespan disorder, with increasing 
proportions of people being referred for assessment for ADHD also in adult 
psychiatry, has led to an urgent need of more knowledge about ADHD in adulthood. 
The question about what causes a disease is not restricted to researchers’ curiosity, but 
is of practical importance also for clinicians as well as society and people affected by 
the disease.  
Together, these aspects have been my main motivation for performing the work 





Attention-deficit/hyperactivity disorder (ADHD) is currently a prevalent diagnosis in 
child psychiatry, typically affecting 2-5 % of school-aged children world-wide. The 
recent and increasing awareness that ADHD may persist to adulthood for a 
considerable proportion of the affected children has created a need for more 
knowledge about ADHD as a lifespan disorder.  
Aims: The aims of the thesis were to: 1) assess occupational functioning among adults 
with ADHD; 2) explore the relationship between ADHD and mood disorders; 3) 
investigate the role of pregnancy- and birth related complications as possible risk 
factors for persistent ADHD; 4) study the effect of an impaired serotonin production in 
utero on the development of ADHD symptoms and related behaviour.  
Material and methods: The thesis is based on four separate articles (Paper I-IV). The 
first two papers are clinical studies based on questionnaires obtained from 414 and 510 
adults with a clinical diagnosis of ADHD, respectively, and controls (n=359/417) from 
the general population. The third paper is an epidemiologic population-based study 
using data from the Medical Birth Registry of Norway (MBRN), in which we 
compared pre- and perinatal risk factors of a national cohort of 2123 adults with 
ADHD and the rest of the Norwegian adult population born in the same time period 
(n=1.17 million). The fourth study explores the possible causative role of reduced 
serotonin production in ADHD related symptoms and behaviour by studying the 
presence and effects of mutations in the tryptophan hydroxylase 1 gene (TPH1) in 
adult ADHD patients, their family members and controls. 
Results:  In paper I we showed that only 24 % of adult ADHD patients (mean age 34.5 
years) were currently in work, compared to 79 % of controls (mean age 29.9 years). 
Having been diagnosed and treated for ADHD in childhood was the strongest predictor 
for being in work as an adult, independently of symptom severity, psychiatric 
comorbidity, and current treatment (OR 3.2, p=0.014). In the second paper, 51 % of 
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ADHD patients screened positive for a bipolar spectrum disorder (BSD) according to 
the Mood Disorder Questionnaire (MDQ), compared to 8.3 % of the controls. Patients 
screening positive for a BSD had lower occupational functioning and significantly 
more drug problems than patients with low levels of affective symptoms.  
In the epidemiological population-based study from the MBRN, we found that low 
birth weight, preterm birth, and low Apgar scores were associated with ADHD in 
adulthood, with the highest risk for the lowest measures. We also found that maternal 
epilepsy and infant oral cleft were associated with ADHD in the adult offspring. 
In the last study, sequencing of TPH1 in 646 adults (patients and controls) resulted in 
the identification of 7 different missense mutations, of which 6 resulted in reduced 
enzyme function in vitro compared to wild type TPH1. Family based analyses showed 
that offspring of mothers with TPH1 mutations had higher levels of ADHD related 
symptoms and behaviour, compared to offspring of fathers with such mutations or 
controls, independently of the individuals’ own TPH1 status. 
Conclusions: Adults with a clinical diagnosis of ADHD had an impaired occupational 
functioning and a high prevalence of comorbid psychiatric problems. Symptoms of 
affective disorders were frequent among adults with ADHD, and were associated with 
lower occupational functioning and more substance abuse. Patients who were 
diagnosed and treated for ADHD in childhood had a more favourable outcome in adult 
life compared to patients who were first diagnosed in adulthood.  
Factors indicating a suboptimal foetal development, such as being born extremely 
preterm or with very low birth weight, were associated with development of ADHD. 
Impaired maternal serotonin production in early embryonic life may be a causative 
pathway in the putative altered brain development, resulting in subsequent ADHD 
related symptoms and behaviours. 
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Attention-Deficit/Hyperactivity Disorder  
Historical perspectives 
Attention-deficit/hyperactivity disorder (ADHD) is the diagnostic term currently used 
to designate a syndrome characterized by symptoms and problems related to attention 
deficits, hyperactivity and impulsivity. The syndrome has received different names and 
definitions during the last century. In 1789, the Scottish physician Alexander Crichton 
described a syndrome characterized by a “mental restlessness”, in which the affected 
individuals showed an “incapacity of attending with a necessary degree of constancy 
to any one object”, and which “almost always arises from an unnatural or morbid 
sensibility of the nerves, by which means this faculty is incessantly withdrawn from 
one impression to another”. Crichton postulated that this condition “may be either born 
with a person or it may be the effect of accidental diseases” 1.  
In 1902, the English paediatrician Sir George Still described a group of children with 
hyperactive, impulsive, often emotionally heightened and socially disruptive 
behaviour, with poor ability of sustained attention and who did not seem to adapt their 
behaviour in response as normally expected to reward and punishment. Still also 
postulated a biological origin to what he called a “morbid defect of moral control”, 
which could be either congenital or acquired by disease in infancy 2.  
Some decades after Still’s description, in the wake of an epidemic outburst of viral 
encephalitis in the North of USA in 1917-18, the term “Post-Encephalitic Behaviour 
Disorder” (PBD) appeared. The term PBD referred to the clinical picture of children 
who were left with significant behavioural and cognitive sequela after surviving this 
brain infection. The syndrome was characterized by a combination of impaired 
attention and regulation of activity, impulsivity and social behaviour 3. This 
observation led to a range of investigations of other possible causes of such a “brain 
damage syndrome”, and associations were found with birth trauma, other brain 
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infections, head injuries, lead toxicity, and epilepsy 4. The terms “Minimal Brain 
Damage” and later “Minimal Brain Dysfunction” (MBD) reflect the view around 1950 
that this syndrome of hyperactivity/restlessness/inattentiveness was considered to be 
the consequence of some kind of brain abnormality, whether or not a history of brain 
damage was present. 
 
Figure 1. Brief history of ADHD 
 
In the following decades, the aspects of inattention and hyperactivity have been more 
or less emphasized in the diagnostic definitions: from Hyperkinetic Behaviour 
Syndrome 5 and Hyperkinetic Reaction of Childhood Disorder in the first official 
recognition of the diagnosis in the Diagnostic and Statistical Manual of Mental 
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Disorders, 2nd edition (DSM-II) in 1968, through Attention Deficit Disorder (ADD) 
with or without hyperactivity in the DSM-III in 1980, to the current Attention-
deficit/hyperactivity disorder (ADHD), recognizing three different subtypes depending 
on the dominant symptom presentation (see Figure 1, brief history of ADHD).  
 
Diagnostic criteria and subtypes of ADHD 
Present diagnostic criteria for Attention-Deficit/Hyperactivity Disorder AD/HD are 
based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, 
text revision (DSM-IV-TR), American Psychiatric Association, from 2000 6, which is 
the diagnostic system used for mental disorders in the USA. In most European 
countries, the present official diagnostic system is the International Classification of 
Diseases, ICD-10 7, where the diagnosis corresponding to AD/HD is named 
Hyperkinetic Disorder. The need for international standards, both in research and 
clinical practice, has led to the widespread use and adaptation of DSM-criteria also 
outside the USA. 
The DSM-IV comprises 3 subtypes of AD/HD; AD/HD predominantly inattentive 
type, AD/HD predominantly hyperactive-impulsive type and AD/HD combined type, 
which require 6 of 9 symptoms of inattention, 6 of 9 symptoms of 
hyperactivity/impulsivity, or 6 of 9 symptoms from both categories (see Table 1). In 
addition, the category AD/HD Not Otherwise Specified (NOS) includes disorders with 
prominent symptoms of inattention or hyperactivity with impairment that do not fully 
meet the formal criteria. The list and grouping of symptoms are similar in the DSM-IV 
and the ICD-10 (except that the symptom “often talks excessively” is classified as a 
symptom of hyperactivity in the DSM-IV whereas it is listed among the impulsivity 
symptoms in the ICD-10). The main difference between the two systems is that the 
ICD-10 requires symptoms from both the inattentive (6 of 9), the hyperactive (3 of 5) 
and the impulsive (1 of 4) clusters for the diagnosis, whereas symptoms and 
impairment from inattention symptoms alone are sufficient for the diagnosis according 
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to the DSM-IV. Also, the ICD-10 is stricter in ruling out ADHD if other psychiatric 
disorders are present at the same time, i.e. if criteria for a mood or anxiety disorder are 
present, hyperkinetic disorder should not be diagnosed. The frequently occurring 
comorbidity with conduct disorder in children with ADHD is, on the other hand, 
regarded as a subtype in the ICD-10, where the term Hyperkinetic Disorders (F 90) 
includes the following specifications; Disturbance of Activity and Attention (F 90.0), 
Hyperkinetic Conduct Disorder (F 90.1), Other Hyperkinetic Disorder (F 90.8) and 
Hyperkinetic Disorder, Unspecified (F90.9). 
 
Table 1. Diagnostic criteria of Attention-Deficit/Hyperactivity Disorder according to DSM-IV 
A. Either (1) or (2): 
(1) Six (or more) of the following symptoms of inattention have persisted for at least 6 months to a 
degree that is maladaptive and inconsistent with developmental level: 
(a) Often fails to give close attention to details or makes careless mistakes in school-work, 
work, or other activities 
(b) Often has difficulty sustaining attention in tasks or play activities 
(c) Often does not seem to listen when spoken to directly 
(d) Often does not follow through on instructions and fails to finish schoolwork, chores, or 
duties in the workplace (not due to oppositional behaviour or failure to understand 
instructions) 
(e) Often has difficulty organizing tasks and activities 
(f) Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort 
(such as schoolwork and homework) 
(g) Often loses things necessary for task or activities (e.g., toys, school assignment, pencils, 
books, or tools) 
(h) Is often easily distracted by extraneous stimuli 
(i) Is often forgetful in daily activities 
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(2) Six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 
6 months to a degree that is maladaptive and inconsistent with developmental level: 
Hyperactivity 
(a) Often fidgets with hands or feet or squirms in seat 
(b) Often leaves seat in classroom or in other situation in which remaining seated is expected 
(c) Often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness) 
(d) Often has difficulty playing or engaging in leisure activities quietly 
(e) Is often “on the go” or often acts as if “driven by a motor” 
(f) Often talks excessively 
Impulsivity 
(g) Often blurts out answers before questions have been completed 
(h) Often has difficulty awaiting turn 
(i) Often interrupts or intrudes on others (e.g. butts into conversation or games) 
B. Some hyperactive-impulsive or inattentive symptoms that cause impairment were present before 
age 7 years. 
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] 
and at home). 
D. There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning. 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental Disorder, 
Schizophrenia, or Psychotic Disorder and are not better accounted for by another mental disorder (e.g., 
Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality Disorder) 
Adapted from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text 




Prevalence of ADHD  
ADHD is one of the most frequently encountered diagnoses in child psychiatry, with 
prevalence rates of 3-7 % in school-aged children, according to DSM-IV 6, and a 
recent pooled prevalence estimate of 5.3 % across studies worldwide 8. However, 
reported prevalence estimates vary substantially between studies and countries (from 
less than 1 % to more than 20 %) 9. Recent data from Norway estimate the prevalence 
of ADHD among 8-10 years old children to be 1.7 % 10. The main explanation for this 
variation is probably differences in practice of assessment; i.e. ICD versus DSM 
criteria; parents or teachers used as informants; impairment criteria included or not, 
age range, gender, and type of population studied 9,11. The prevalence rates are 
generally higher for DSM-based diagnoses, since all children diagnosed with ICD-10 
hyperkinetic disorder will be included in the DSM-IV ADHD criteria, but not vice 
versa (i.e. ADHD predominantly inattentive subtype is excluded in ICD-10) 12,13. A 
prevalence of 2-5 % thus represents a reasonable estimate of the prevalence of ADHD 
in children across populations. 
Until recently, ADHD was considered to be a childhood disorder. In his description of 
The Hyperkinetic Reaction of Childhood Disorder in 1957, Laufer wrote that the 
disorder has a “good prognosis” and “often disappears after puberty” 5, and the DSM-
II stated that “it usually diminishes in adolescence” 14. Still, during the last decades, 
follow-up studies have shown that many children with ADHD continue to have 
impairing symptoms also in adolescence and adulthood. However, to what extent 
ADHD persists over the life span has not yet been established. In a meta-analysis of 
the earliest follow-up studies of children with ADHD, the actual proportions of 
children who retained an ADHD diagnosis at follow-up in late adolescence and young 
adulthood varied from 8-72 % 15. Again, this variation appears to depend on 
methodological differences in the assessment of ADHD, including the use of different 
editions of the DSM at baseline and/or at follow-up. Persistence rates of ADHD have 
shown to be much higher when parent reporting is used, as compared to self-report 
from the young adults themselves 16. In a recent review, Faraone and colleagues 
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confirmed the age dependent decline of ADHD diagnosis, and showed that the 
persistence rates depended much on the definition being used; from ~15 % persistence 
at age 25 years if maintenance of full diagnostic status was required (i.e. syndromatic 
persistence), to ~ 40-60 % persistence if partial diagnostic status with impairment was 
required (i.e. symptomatic persistence, corresponding to residual ADHD in the DSM-
IV) 17. With a prevalence estimate of 5 % in childhood, the deduced prevalence of 
ADHD in adults would range from less than 1 % for the full syndrome to about 2.5 % 
for the residual state of ADHD. These projected prevalence estimates are lower than 
found in recent cross-sectional studies of adult populations, which reported 
international prevalence rates of adult ADHD between 2.5 and 4.4 % 18-20. Thus, the 
question may be raised whether ADHD seen in self-referred adults represents the same 
condition as ADHD seen in childhood 16. 
 
Clinical aspects of adult ADHD 
 
The diagnostic assessment of ADHD may be challenging for several reasons. First, 
according to current definitions, ADHD is a disorder that starts in childhood (see Table 
1, criterion B). A diagnosis of ADHD in adulthood should therefore not be made 
unless there also is a childhood history of symptoms of ADHD. This may, however, be 
difficult to document retrospectively, because the recall and insight of own behaviour 
in childhood may be inaccurate, and because informants who were close to the person 
in childhood may be unavailable. Second, although diagnostic criteria for ADHD state 
that symptoms should be “maladaptive and inconsistent with developmental level”, 
they are based on symptoms and behaviour observed in children 21. Follow-up studies 
of children with ADHD have shown that the course and pattern of symptoms change 
over time. While motor hyperactivity seems to attenuate during late adolescence and 
adulthood, attention problems are more persistent and may even increase 22,23. The 
core symptoms may also have other manifestations in adults than in children and 
thereby be more difficult to recognize as ADHD symptoms. For example, 
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hyperactivity symptoms may be limited to fidgetiness or an inner feeling of 
restlessness rather than moving around, or to the inability to relax or sensation seeking 
behaviour and intolerance of boredom. Impulsivity and stimulation-seeking behaviour 
may have more serious consequences in adults than in childhood, such as reckless 
driving, terminating valuable relationships or quitting jobs without careful 
consideration. Attention problems in adults are often manifested as difficulties 
remaining focused in conversations or tasks, being easily distracted and having 
difficulties getting organized. Other typical features in adults with ADHD, not 
mentioned specifically in the DSM-IV, are procrastination and problems with time 
management. Underachievement and low self-esteem are often reported. These ADHD 
symptoms may actually be more impairing in adult life, when demands and 
expectations to one’s self-organizing ability is increased relative to childhood, where 
the structure from school and parents may compensate for the lack of own, inner 
structure. As stated by Weiss et al., “It is exactly this difference between what is 
expected of children and what is expected of adults that makes it hard to diagnose 
adult ADHD using childhood criteria” 24.  
In a comprehensive report on adult ADHD, Barkley et al. presented and compared data 
from two extensive studies on clinically referred adults with ADHD, and children 
diagnosed with ADHD followed to adulthood, respectively. They demonstrated the 
lack of sensitivity of current DSM-criteria for adults with ADHD, both regarding the 
formal cut-off of 6 of 9 symptoms from each symptom cluster, and the age-of-onset 
requirement of 7 years. Based on factor analytic models, they propose a novel set of 
diagnostic criteria for adults, which better delineate ADHD from the healthy 
population, and better distinguish the disorder from other clinical populations 16.  
According to Barkley et al., and reflected in their proposed criteria, the core problem 
in ADHD is a deficit of executive function (EF), or more fundamentally, of response-
inhibition. Executive functions may be broadly defined as “a set of neurocognitive 
processes that allow for the organization of behaviour across time so as to attain future 
goals” 25. Thus, it is not the hyperactivity, often the most obvious symptom in children, 
but rather the distractibility, the impulsive decision making, and the impaired ability to 
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adjust their behavioural responses appropriately to a situation, which seem to best 
distinguish adults with ADHD from adults without ADHD.  
 
Affect lability and emotional dysregulation 
 
Adults with ADHD commonly present with additional symptoms to those required by 
the formal diagnostic criteria, but which may often be as impairing as the defined 
ADHD core symptoms. These symptoms, mainly related to affective lability or 
emotional dysregulation, were included in the earliest descriptions of ADHD in 
children 2,5 and are currently listed as associated features of ADHD in the DSM-IV. In 
their early reports on adults with persistent ADHD followed up from childhood, 
Wender and colleagues proposed a new set of diagnostic criteria aimed to better reflect 
the adult phenotype of ADHD 26. These Utah-criteria require the presence and 
persistence of both motor hyperactivity and attention problems in childhood and in 
adulthood for the diagnosis, in addition to at least two of the following five 
symptoms/problems; mood instability (mood shifts that last for hours or at most a few 
days), disorganization or inability to complete tasks, hot temper (anger outbursts, 
easily irritated), emotional over-reactivity (difficulty dealing with ordinary stresses of 
life), and impulsivity (such as impulsive buying, other hasty business decisions, 
driving behaviour, initiation or termination of relationships). Wender and colleagues 
also developed the Wender Utah rating scale (WURS) as a tool for the retrospective 
assessment of childhood ADHD 27, emphasizing the importance of tracing symptoms 
back to childhood. Despite meeting a need for adult adjusted criteria for ADHD at the 
time, the use of the Utah criteria have been limited, probably because they fail to 
identify the predominantly inattentive subtype of ADHD, and because they may not 
adequately delineate ADHD from affective disorders 28. The emotional aspect of 
ADHD however still reflects the clinical reality for patients with ADHD and their 
clinicians, and is associated with a more severe course and outcome of the disorder 
25,29-31
. A topical question is how these emotional symptoms should best be 
understood; as an associated trait in a subgroup of patients (DSM-IV), as part of a 
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comorbid 32, or even primary affective disorder 33, or as a main feature of ADHD 
25,34,35
 (see Discussion of main findings). 
 
Comorbidity and overlap with other psychiatric disorders 
 
Attention-deficit/hyperactivity disorder frequently co-exists with other problems and 
psychiatric disorders, and this is particular true in adulthood. About 80 % of ADHD 
patients in clinical settings fulfil criteria for at least one, and approximately 50 % for at 
least two other DSM-IV diagnoses 16,36,37. Comorbidity is also common in non-referred 
and community samples of adults with ADHD 16,19. The most frequent co-occurring 
diagnoses are mood and anxiety disorders, substance use disorders (SUD) and 
personality disorders 19,38,39.  
Mood (or affective) disorders are grouped into unipolar and bipolar disorders (BD), 
the first comprising depressions only, the latter characterized by alternations between 
depressive periods and periods of elevated mood and energy, i.e. mania (bipolar 
disorder 1, BD 1) or hypomania (bipolar disorder 2, BD 2). Attention-
deficit/hyperactivity disorder and BD have several common features; they are both 
heritable disorders 40,41,42, their core symptoms involve a dysregulation of energy, 
activity, impulsivity, mood and attention 6, and both disorders often co-occur with 
other psychiatric disorders and problems 19,43-45, i.e. SUD 46-49 and anxiety disorders 50-
52
. A main distinguishing feature between ADHD and BD is the periodicity of 
symptoms (state-like) in BD, contrasted to the chronic symptom course (trait-like) in 
ADHD. However, in recent years the concept of BD has been extended, including 
patients formerly diagnosed with unipolar depression 53. There is now increasing 
evidence that affective temperaments, life-long dysregulation of mood, and other 
chronic symptoms are important parts of the phenomenology of the bipolar spectrum 
disorders (BSD) 54,55. Another distinguishing feature between ADHD and BD is the 
age of onset, which typically is in late adolescence or young adulthood in BD, and 
before school age in ADHD. Interestingly, child psychiatrists are currently discussing 
the diagnostic criteria and phenomenology of BD in children, where the broadly 
defined juvenile BD seems to have more overlapping features and to be more 
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comorbid with ADHD than the narrow defined BD, which is based on the classical 
adult criteria for BD 56-58.  (For further discussion of this topic, see Discussion of main 
findings). 
Substance use disorders (SUD) are frequently reported among adults with ADHD. In 
clinical samples of adults with ADHD, lifetime prevalence of alcohol abuse or 
dependence varies between 17 and 53 %, and for other drugs between 8 and 32 % 16,59-
61
. In community-based samples, 15 % of adults with ADHD report a lifetime history 
for any substance use disorder compared to 6 % of adults without ADHD 19. 
Symptoms related to substance misuse may be difficult to distinguish from primary 
ADHD symptoms, and ongoing substance use is a clinical challenge in the diagnostic 
assessment and the treatment of ADHD. The development of SUD in children growing 
up with ADHD seems to be partly mediated by the presence of symptoms of conduct 
disorder and of juvenile BD in adolescence. Comorbidity with SUD is further 
associated with antisocial behaviour and low functioning, including criminality, in 
adult life 59,62,63,64. Some studies indicate that this malignant course of ADHD may be 
reduced by treatment with central stimulants (CS) in childhood 65, but more 
prospective studies are needed to clarify this important issue. 
Anxiety disorders are also reported more often among children and adults with ADHD 
than in the general population 19,66,67. Anxiety as a trait may be considered antagonistic 
to impulsivity, whereas anxiety and attention are closely related. The combination of 
ADHD and anxiety seems to be more linked to the inattentive subtype, to have a 
different cognitive profile and possibly also be caused by other risk factors, than the 
combined and hyperactive-impulsive subtypes of ADHD 16,52,68,69. Differentiation 
between ADHD and anxiety may however be difficult in the clinical setting, especially 
since both disorders may appear early in life: Is the anxiety secondary to a 
disorganized and chaotic life due to a primary ADHD, or is the inability to concentrate 
and achieve secondary to a primary anxiety disorder? 70 In adults, some anxiety 
disorders (panic disorder, generalized anxiety disorder) have shown to be more 
specifically related to bipolar spectrum disorders 71. This indicates a putative link 
between mood, anxiety and attention that may be relevant for ADHD.  
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In the multidimensional DSM, ADHD is classified as an axis I disorder, but the 
description of this long lasting trait is semantically close to the axis II personality 
disorders used in adult psychiatry 72. Indeed, it has been shown that many children 
with ADHD as adults are diagnosed with personality disorders, in particular the cluster 
B personality disorders (i.e. antisocial and borderline) 38,73-76. Features related to 
impulsivity and poor self-regulation (affect instability, lack of organization, impaired 
social relationships) are characteristics of both ADHD and borderline personality 
disorder (BPD), although not included in the current diagnostic criteria for ADHD. 
This may suggest that the axis II disorders arise as complications of insufficiently 





According to current guidelines, the first line treatment in mild to moderate cases of 
ADHD in children and adolescents is parent training/education programmes for carers 
and psychological and/or social skills training for the child or adolescent 77,78. 
Psychosocial interventions should also be the first treatment for adults with ADHD 
with mild symptoms and impairment. Cognitive behavioural therapy (CBT) has shown 
to be effective in reducing persistent symptoms in adults after stabilization with 
medication 79,80. 
For severe cases of ADHD in children (except preschoolers), and moderate to severe 
cases of ADHD in adults, medication is considered the first line treatment. Since the 
discovery of amphetamine’s calming effect on hyperactive children in 1937, and the 
approval of methylphenidate for treatment of behavioural disorders in children in the 
beginning of the 1960s, central stimulants (CS) have been the drugs of choice in the 
treatment of ADHD/hyperkinetic disorder 81. New developments in the 
pharmacotherapy of ADHD have so far mainly been related to alterations in 
composition and release properties of these CS 82. Although CS are the most effective 
drugs in treating ADHD on a group basis 83, the more recently introduced non-
stimulant drug atomoxetine has also shown to be effective and may be a useful 
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alternative for non-responders, or cases where stimulants should be avoided (e.g. 
ADHD comorbid with anxiety or SUD 84,85). Other drugs that have been used less 
frequently include some antidepressants (buproprion, tricyclic antidepressants) and 
antihypertensives (clonidine, guanfacine) 86. All of the above mentioned drugs act on 
the catecholaminergic system. In contrast, the widely used selective serotonin reuptake 
inhibitors (SSRI) in adult psychiatry do not have any documented effect in reducing 
core ADHD symptoms 87. Despite the existence of effective treatment for reducing 
core symptoms of ADHD, there is still a need for studies that evaluate the long-term 
effects of pharmacotherapy on function and impairment, and studies on ADHD 
patients with comorbid disorders 88-90. 
 
Neurobiology of ADHD  
 
Brain regions and networks 
 
ADHD is often considered a neurodevelopmental disorder, i.e. the symptoms and 
behaviour are caused by a disturbed development of the brain. Imaging of the brain 
with magnetic resonance techniques (MRI) has shown that children with ADHD on 
average have a reduced overall brain volume of about 3-4 % compared to control 
children 91,92. The most prominent and consistent structural deficits in ADHD in 
children have been found in the frontal lobes (in particular the prefrontal cortex), the 
basal ganglia (striatum), and more recently also in the cerebellum, the anterior 
cingulate cortex and the corpus callossum 93-96. Longitudinal studies have shown that 
normal maturation of the brain cortex is delayed by about 3 years in children with 
ADHD compared to controls 97, and cross-sectional studies have shown that cortical 
thickness is reduced in children, adolescents and adults with ADHD 98. Deficits in 
response inhibition and of executive functions are, as mentioned, considered a core 
problem in ADHD 99. Functional MRI has made it possible to localize these executive 
functions not only to the prefrontal areas of the brain, but also to fronto-striatal, and 
  
26 
fronto-subcortical-cerebellar networks. These areas seem to be underactivated in 
children with ADHD compared to controls during performance of tasks involving 
attention and disinhibition 100,101. Differences in volume and shape of the hippocampus 
and the amygdala have also been found in children with ADHD, suggesting an 
involvement of the “emotional” limbic system in the disorder 102. Although fewer in 
number, studies of adults with ADHD confirm these brain abnormalities 103-105. 
Furthermore, it seems that the observed dysfunctions in children and adults with 
ADHD are not restricted to isolated brain regions but to compromised inter-regional 




Several neurotransmitters seem to be involved in the pathogenesis of ADHD, of which 
the monoamines, and in particular the catecholamines have been the most studied. The 
main reason for this is that the central stimulant drugs methylphenidate and 
amphetamine act indirectly as dopamine (DA) and noradrenaline (NA) agonists, 
mainly by blocking the reuptake of DA and NA in the synapses 108-111. The 
noradrenergic system is also the main target of the selective NA reuptake inhibitor, 
atomoxetine, a more recently introduced drug in the treatment of ADHD.  
Dopamine is involved in the regulation of cognition, movement, reward and 
motivation, whereas NA is important for arousal and for sensory information 
processing, all considered central aspects of ADHD psychopathology. Dopaminergic 
neurons originate mainly in the brain stem and the hypothalamus. Their axons are 
connected to other brain regions by dopaminergic pathways, of which the mesocortical 
and the mesolimbic seem to be the most important in ADHD. The axons of the 
noradrenergic neurons in the locus coeruleus also project to various regions of the 
brain including the prefrontal cortex, the cingulate gyrus, the striatum, the amygdala 
and the hippocampus.  
The monoamine serotonin is also involved in a variety of behaviour and brain 
functions, such as impulsivity, aggression, mood, cognition and sleep. Serotonergic 
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neurons originate in the raphe nuclei in the brain stem and project extensively 
throughout the brain in a diffuse modulatory system 112. Serotonin as a 
neurotransmitter has been widely studied in mood- and anxiety disorders, but has so 
far received less attention in ADHD. However, there is evidence that serotonin may 
have a separate contribution to aspects of the ADHD phenotype 113,114. Experiments on 
dopamine transporter (DAT) knockout mice have indicated that the calming effect of 
stimulants on dopamine related hyperactivity is mediated by serotonergic activity 115, 
and that serotonin modulates the effects of dopamine in the reinforcing/addictive 
elements of drug-taking behaviour 116. A putative role of serotonin in ADHD thus 
would be through a disturbed balance and/or interaction with the other catecholamines 
within different regions of the brain 117-119. Most of the serotonin in the body is 
however synthesised outside the brain, localized mainly in the gastrointestinal tract 
and blood platelets 120. Importantly, the effects of serotonin on ADHD may extend 
beyond that of defective or altered neuronal signalling. Rodent data have shown that 
serotonin is crucial for normal embryonic brain development 121, and findings 
presented in this thesis suggest that low maternal serotonin production in pregnancy 
may have lasting effects on neuropsychiatric symptoms and behaviour (Paper IV). 
Still, the specific role of serotonin in the development of ADHD remains to be 
elucidated. 
 
Risk factors of ADHD 
 
Attention deficit/hyperactivity disorder is considered a complex trait disorder, with 
heterogeneity both in its clinical expression and etiological pathways. As early as in 
1902, Still noted that the origins of the disorder could be congenital or acquired, either 
by disease in early infancy or by later trauma. Based on family, adoption and twin 
studies, it is now generally acknowledged that ADHD is of familial origin in most 
cases, with summarized data from twin studies reporting a heritability estimate of 





Inspired by the high heritability rates and putative monoaminergic dysfunction in 
several psychiatric disorders, numerous association studies on candidate genes have 
been performed on ADHD. The most studied candidate genes in children with ADHD 
are related to the dopamine system. Some significant associations across studies have 
been found for the dopamine transporter (SLC6A3/DAT1), the dopamine D4 receptor 
(DRD4) and the dopamine D5 receptor (DRD5) genes 122. Other genes from the 
noradrenergic (DBH, SLC6A2/ NET, ADRA2A) and serotonergic systems 
(SLC6A4/SERT, HTR1B, TPH1, TPH2) have also been associated with ADHD in 
children 122. However, results have been inconsistent and none of these findings have 
so far reached whole genome significance (defined to P<5x10-8 when using 106 
markers) 123. Heterogeneity across studies may represent random variations and 
methodological differences. It should however be further explored, as it may also 
reflect differential involvement of genes in different subgroups of patients 122,124.  
Whereas candidate gene studies are hypothesis driven, scanning of parts or the whole 
of the genome without predefined hypotheses may be useful to explore “new” 
associations of genes to a disorder. Linkage studies have identified several 
chromosomal regions associated with ADHD, some of which have been reported in 
multiple studies (5p13, 14q12, 17p11) 125. The only chromosome region reaching 
genome-wide significance in a meta-analysis of all genome-wide linkage scans 
performed until 2008 (7 studies, 2084 individuals in total) was located on chromosome 
16 (16q21) 125. Interestingly, none of the more than 200 genes located within this 
region, had previously been considered as candidate genes for ADHD 125. Six whole 
genome wide association studies (GWAS) have so far been published on ADHD 
(September 2010); five in children 126-130 and one in adults 131. No single gene marker 
reached genome-wide significance in meta-analyses of these studies, and little overlap 
was found between the studies 123,132. Again, none of the classical neurotransmitter 
candidate genes were on the list of the genes with strongest association to ADHD. The 
authors also compared a list of a priori defined candidate genes. Although none of 
them reached whole genome significance, there was a slight inflation of low p-values 
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among the candidate genes, which suggests that some of these genes may harbour a 
true association signal. The highest ranked gene in this meta-analysis of candidate 
genes (and the only gene overlapping between the GWAS) was the CDH13, which 
interestingly is located in chromosome 16, i.e. in the peak region from the meta-
analysis of linkage studies of ADHD. The CDH13, which encodes a cell adhesion T-
cadherin involved in cell motility and growth 133,134, has previously been associated to 
alcohol and drug abuse 135. Thus, findings from GWAS have guided the attention 
towards new genes, some of which seem to be related to the development and function 
of the nervous system 132.  
In view of the initial optimism, the rapidly evolving technology and the continuous 
efforts in genetic research on ADHD, the results in the search for a genetic 
underpinning of ADHD and other complex disorders have so far been disappointing. 
The polygenetic and multifactorial etiology, and the heterogeneous phenotype of 
ADHD (characteristics of complex trait disorders), is probably the main reason for the 
lack of identification of genes that confer a major risk. Common genetic risk variants 
(polymorphisms) may be difficult to identify because the effect of each gene variant is 
small (low penetrance) and may increase the risk for a disease only when interacting 
with other genetic or environmental factors. Importantly, if a strong association is 
found between a disease and single nucleotide polymorphisms (SNPs), the function of 
the gene may still be unknown. Rare gene variants (mutations) which each may be 
more strongly associated to the disorder (higher penetrance) are more difficult to study 
in association studies, because each variant is present only in a small number of 
individuals (Figure 2). However, if identified, they may be very useful in elucidating 
pathogenetic mechanisms of the disease since they may be linked more directly to the 
phenotype. Thus, whereas only weak associations were found between common 
variants of TPH1 or TPH2 in a recent large association study of adult ADHD 136, a 
study of functional, rare variants (missense mutations) within the same genes were 
found to be associated with ADHD (Paper IV). Likewise, Elia et al. studied rare copy 
number variants (CNV) in ADHD patients. They found that these variants were more 
likely to affect genes that have also been implicated in other neuropsychiatric disorders 
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(autism, schizophrenia, epilepsy). They thus concluded that rare CNVs could play an 
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Figure 2: Disease susceptibility related to frequency of genetic risk variants. The genetic contribution 
in common (complex) diseases is typically based on the sum of several common gene variants acting 
together in increasing the vulnerability for the disorder. The effect of the individual gene is small, and 
is therefore difficult to detect in (genome wide) association studies. Figure adapted from McCarty et 
al., by permission from Macmillan Publishers Ltd: Nat Rev Genet, copyright 2008 138.  
 
Environmental risk factors  
 
A heritability estimate of 75 % implies that at least 25 % of the etiology of ADHD is 
due to non-genetic (acquired, environmental) risk factors. Several environmental risk 
factors have been associated with ADHD, spanning from psychosocial stressors, to 
physical injuries or exposure to toxins to the brain 139,140. Environmental risk factors 
may be ‘shared’ (by several individuals, siblings) or ‘non-shared’ (unique to the 
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individual). The ‘non-shared’ risk factors seem to be most important in the 
development of ADHD 141,142. Environmental risk factors may further be classified as 
pre-, peri- or postnatal, depending on their period of influence relative to birth. Table 2 
shows risk factors that have been associated with ADHD. Postnatal factors include 
brain trauma and infections (cf. post-encephalitic brain disorder, minimal brain 
damage), endocrine and metabolic disorders (thyroid dysfunction, phenylketonuria), 
toxins (PCB, lead), nutritional factors (deficiencies, additives, diet style) 143-147. 
Psychosocial factors such as low social class, parental marital conflicts, maltreatment 
and emotional trauma during childhood, are also associated with ADHD, in particular 
when several such factors occur together 148,149. Although they may increase symptoms 
and problems related to hyperactivity and inattention, further research is required 
before the role of acquired risk factors’ role in the etiology of ADHD can be 
established. 
 
Pre- and perinatal environment 
 
Pre- and perinatal factors are particularly attractive as “candidate” environmental risk 
factors for neurodevelopmental disorders because of their potential influence on the 
developing brain 150,151. Several maternal life-style factors during pregnancy have been 
associated with ADHD in the offspring (Table 2), of which maternal smoking has been 
the most reported 152-155. Growth retardation, preterm birth and low birth weight have 
also been widely studied and correlated to increased risk of ADHD and ADHD 
symptoms in later childhood 156-158 and adolescence 159,160. Little is known, however, 
about these factors in relation to ADHD persisting to adulthood. Other interesting yet 
less studied factors are maternal somatic disease and metabolic or endocrine 
dysfunction, such as epilepsy (Paper III), thyroid dysfunction 161, phenylketonuria 162 





Table 2. Environmental risk factors that have been associated with ADHD 
Prenatal risk factors Alcohol in pregnancy 
 Smoking in pregnancy 
 Drug use in pregnancy  
 Medication (thyroid medication) 
 Maternal somatic conditions (epilepsy, thyroid 
disorder, phenylketonuria, obesity) 
 Maternal stress during pregnancy 
 Lead exposure 
 Growth retardation  
 Bleeding in pregnancy 
 
Protracted/complicated delivery 
Perinatal risk factors Low birth weight 
 Preterm birth 
 Low Apgar score 
Postnatal risk factors Cerebral trauma 
 Infections (encephalitis, meningitis, otitis media) 
 Nutritional factors (nutritional deficiencies, food 
additives, food sensitivities)  







Genes and environment  
 
Since the impact of individual genetic and environmental risk factors in ADHD is only 
small or moderate in size, their contribution is likely through an additive and /or 
interacting effect in a multifactorial etiological model. This may be gene-gene, 
environment-environment, or gene-environment interactions, and the effect of one 
factor may be either mediated, or moderated, by the presence of the other factor. In the 
case of ADHD, gene-environment interactions have been found between; low birth 
weight (LBW) and the catechol-O-methyl-transferase gene (COMT) in predicting anti-
social behaviour in children with ADHD 163; maternal smoking in pregnancy and 
polymorphisms in dopaminergic genes (DAT, DRD4) 164 and the nicotinic receptor 
gene (CHRNA4) related to the combined subtype of ADHD, respectively 165. 
Interaction between serotonergic gene variants (SERT, TPH2) and burden of life 
events seem to predict the presence of co-occurring personality traits and personality 
disorders in adult ADHD patients 72, and both dopamine and serotonin transporter 
genotypes may modify effects of maternal expressed emotions on emotional and 
conduct problems in children with ADHD 166. These studies illustrate the possible 
benefits of studying limited phenotypic aspects of a complex disorder like ADHD, 
which may have different risk factor profiles. However, the exploratory nature of these 
studies calls for replications before conclusions can be made. Further functional and 
experimental studies are required before these risk factors can be considered true 
pathogenic factors 167. 
 
Persistence of ADHD 
 
Risk factors causing a disease are not necessarily the same as the risk or protective 
factors influencing the course of the disease over time 168. Clinical studies have shown 
that the severity of ADHD (symptom severity, functional impairment) and the 
presence of psychiatric comorbidity and childhood adversities (including parental 
psychopathology) are associated with persistence of ADHD to adulthood169-171. Little 
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is known, however, about specific risk factors. Although it has been suggested that 
ADHD persisting to adulthood may be more heritable than ADHD that remits during 
adolescence 172, recent twin studies of adults have reported lower heritability rates than 
those found in child studies 173-175 (Larsson et al., unpublished data from Swedish 
sample of 15.000 twin pairs). Furthermore, recent large-scaled association studies of 
adults with ADHD have not been able to replicate the most established genetic 
findings from previous research in childhood ADHD relating to dopaminergic genes 
132,176
. A study of serotonergic candidate genes in a combined sample of children and 
adults with ADHD revealed that some genes were associated only to adult ADHD 
(MAOB), others with the combined subtype of ADHD in both adults and children 
(5HT2A), and others again to adults and children with ADHD in general (DDC) 177. It 
is not clear, however, whether these findings reflect differential effects of genes across 
the life span, methodological differences between studies, or differences in assessment 
of the ADHD phenotype in children and adults (self-report versus informant reports) 
178
.  
Environmental risk factors have been less studied in adults with ADHD. 
Methodological challenges in the assessment of risk factors in adults include the fact 
that the number and hence the complexity of potential and interfering exposures will 
accumulate over time, and the problem of recall bias. Further research exploring 
potential differences between risk profiles of ADHD remitting in childhood versus 
ADHD persisting to adulthood would however be of interest.  
  
35 
The present study 
 
The present study is part of the multi-disciplinary study “ADHD in adults in Norway; 
from clinical characterization to molecular mechanisms” initiated at the University of 
Bergen in 2004. The main motivation for conducting this study was a strong need for 
more knowledge about ADHD in adulthood, which appeared as a “new” diagnosis 
encountered in adult psychiatry at the time of the initiation of the study. The 
heterogeneity in the clinical presentation of adults with ADHD motivated both the 
primary clinical descriptions and the search for possible risk factors. The general aim 





I. Characterization of clinically diagnosed ADHD patients: 
 To describe occupational functioning among adults with ADHD, and to examine 
the effects of symptom profile and treatment on their functioning (Paper I) 
 To investigate the comorbidity and relationship between bipolar disorder (BD) and 
ADHD (Paper II) 
II. Investigation of pre- and perinatal risk factors in adult ADHD: 
 To determine the association between complications in pregnancy and delivery and 
ADHD persisting to adulthood  (Paper III) 
 To investigate the possible role of reduced serotonin production on ADHD related 





Materials and methods 
 
The present study is based on a cross-sectional case-control design of a nation wide 
sample of adults with ADHD and a population-based control sample. Paper IV 
additionally includes family members of ADHD patients, and Paper III uses a registry 
based nested case-control design.  
 
Patients  
We aimed at gathering a naturalistic patient sample as encountered in general clinical 
practice. Two main sources of patient recruitment were used; the registry of the former 
diagnostic committees (Expert Committees of Hyperkinetic Disorder) and clinicians 
(mainly psychiatrists) nationwide.  
The Expert Committees of Hyperkinetic disorder /ADHD 
The prescription of central stimulants (CS) for adults was legally restricted in Norway 
until 1997. From October 1997 to May 2005, adults (≥18 years) with ADHD/ 
Hyperkinetic disorder were allowed to receive CS only after a systematic and 
mandatory diagnostic evaluation by one of three regional diagnostic committees; i.e. 
the Expert Committees for Hyperkinetic Disorder/ ADHD 179. Patients were referred to 
the committees by their psychiatrists, general practitioners or hospital doctors. Each of 
the diagnostic committees consisted of three to five clinicians (mainly psychiatrists 
and neuropsychologists), with special experience on diagnosing ADHD in children 
and adults. A few pioneering clinicians also diagnosed and treated adult patients with 
ADHD in addition to the committees (on special permissions). 
Diagnostic assessment 
The referral procedure to the expert committees required both thorough descriptions of 
the patient’s current symptoms and functioning and informant information about 
childhood behaviour and functioning. Results from physical and psychiatric 
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examinations were also required. The expert committees then reviewed the patient’s 
records to confirm, or disprove, the diagnosis of ADHD. A formal conclusion was 
made recommending or not recommending treatment with central stimulants, based on 
a confirmed diagnosis and the absence of contra-indications for such treatment (mainly 
psychosis or ongoing substance abuse). The diagnostic assessment was done according 
to the ICD-10 research criteria for Hyperkinetic Disorder, with two modifications; 
allowing the inattentive subtype as sufficient for the diagnosis and allowing the 
presence of comorbid psychiatric disorders as long as the criteria for ADHD were 
fulfilled and present before the appearance of the comorbid disorder. This diagnostic 
assessment strategy was chosen as a compromise between the fact that ICD-10 was the 
official diagnostic system used in Norway, and the need to have an assessment 
comparable with the international DSM-IV standards (O.B. Fasmer, personal 
communication). 
The data from the Expert Committees of Hyperkinetic Disorder /ADHD were not 
primarily designed as a patient registry, but due to the compulsory referral system for 
adults considered for medical treatment for ADHD, it still constitutes a national cohort 
of adult ADHD patients. During almost eight years, the committees handled more than 
5000 patient referrals, and nearly 70 % were recommended for treatment (n = 3397). 
In May 2005, National Guidelines for Diagnosing Lifespan ADHD were implemented 
by the Norwegian Health Authorities. Since then the diagnosis and treatment of adult 
ADHD was handled by individual specialists in psychiatry and psychology without the 
direct involvement of the former expert committees. 
Recruitment to the present study  
Based on the address lists from the Expert Committees of ADHD/Hyperkinetic 
disorder, patients all across Norway were invited directly by posted mail to join the 
project. A total of 1700 invitations were sent to patients (mainly to those diagnosed 
after the year of 2000) from 2005 to 2007. By December 2007, 338 (19.9 %) of the 
invited patients had returned completed questionnaires and were included in the study. 
Clinicians (general practitioners, psychiatrists and psychologists) from all over the 
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country were also invited to recruit patients with a verified diagnosis of adult ADHD 
(mainly from out-patient clinics in the period from June 2004-September 2006).  
The inclusion criteria for patients were: 
1) A diagnosis of ADHD or Hyperkinetic Disorder received in adulthood confirmed by 
a clinician outside the project according to DSM-IV or ICD-10 criteria. 
2) Age ≥ 18 years at the time of inclusion. 
There were no formal exclusion criteria.  
Patient recruitment to the project started in 2004 and is still going on at present time. 
The first 420 recruited patients were included in Paper I, the first 510 in Paper II, and 
the first 459 patients in Paper IV. The patient sample in the epidemiologic study in 
Paper III includes all patients from the registry of the Expert Committees who were 
found eligible for treatment with central stimulants and who were born between 1967 




The control persons used in this study are individuals randomly recruited from the 
general population in Norway having the same age range as the patients (Paper I, II, 
IV), and a whole population cohort in Paper III.  
The Medical Birth Registry of Norway (MBRN) 
The MBRN is based on compulsory notification of all births in Norway from 1967. 
During January and March 2007, 2163 invitation letters were sent out to a randomly 
selected sample of the Norwegian population between 18 and 40 years old, using the 
MBRN as the basis. By December 2007, 417 of these (19.3 %) had responded with 
completed questionnaires and were included in the study. The control sample in the 
present study consisted of the first 359 recruited controls by this procedure in Paper I, 
and the first 417 in Paper II. In Paper IV, the sample of 606 controls additionally 
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included 189 controls recruited from other sources (friends of patients, n = 44, students 
n = 139, and 6 ‘other’). In Paper III, the control group consisted of the whole 
population born in Norway between 1967 and 1987, registered in the MBRN, and who 




Family members of patients were invited via patients (probands) to participate in the 
family study of the main project. The families included in Paper IV were families of 
probands with TPH 1 mutations, and in which at least three family members agreed to 
participate. Seven families with a total of 86 members were included. 
 
Figure 3.  Flow chart of included subjects in Papers I-IV  
Eligible for treatment
N = 3397  
Born 1967-1987
N = 1.170.073  
Born 1967-1987 
N = 2323
Epidemiological study (Paper III)













Family members of patients
N= 97
Clinical studies (Paper I and II)
Paper I: Patients n = 414, Controls n = 359
Paper II: Patients n = 510, Controls n = 417
Family/mutational study (Paper IV)
Patients n = 459, Controls n = 606, Family n = 97
National Registry of Adults with ADHD 
N ≈ 5000 (total referrals 1997-2005)
Medical Birth Registry of Norway








All participants included in Paper I, II and IV filled in questionnaires for past and 
current ADHD symptoms, symptoms of bipolar disorder (BD), and questions about 
lifetime co-existent disorders and problems, as well as sociodemographic data 
including educational and occupational activity. A sample of blood or saliva was 
collected for further genetic analyses. No information was obtained directly from the 
patients or controls in the registry based study in Paper III.  
The following self-report questionnaires were used in this study (Papers I, II, IV): 
The Wender Utah Rating Scale (WURS): The WURS is designed to retrospectively 
assess symptoms and signs of ADHD in childhood. The version of the scale used in 
this study contains 25 items and has been validated by several investigators in different 
countries and populations. Each of the 25 questions is rated on a 5-point severity scale 
(0 = not at all/very slightly, 4 = very much). 
The Adult ADHD Self Report Scale (ASRS): The ASRS is the World Health 
Organization’s (WHO) rating scale for adult ADHD designed to measure current 
ADHD symptoms. It consists of 18 items based on DSM-IV symptoms/criteria for 
ADHD that are measured on a 5-point scale (0 = never/seldom and 4 = very often). 
The items 1-9 cover the symptoms of inattention; item 10-18 the symptoms of 
hyperactivity and impulsivity.  
The Mood Disorder Questionnaire (MDQ): The MDQ is a screening instrument for 
bipolar spectrum disorders, BSD (i.e. BD I, BD II, BD not otherwise specified (BD 
NOS), and cyclothymia) for use in the general population and in psychiatric patient 
populations. The MDQ has been validated in both population-based and clinical 
samples 180,181. The MDQ consists of 15 items; the first 13 questions are about lifetime 
symptoms of mania or hypomania, and the last two about co-occurrence of symptoms 
and ranking of functional impairment caused by the symptoms. Question 1-14 is 
answered by ‘yes’ or ‘no’, question 15 by a 4-point severity scale. A positive MDQ 
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score is defined as 7 or more ‘yes’ on the first 13 items, ‘yes’ on question 14 (co-
occurrence of symptoms) and level ‘3 or more’ on question 15 (moderate to severe 
impairment).  
The WURS, ASRS and MDQ have not yet been officially validated in Norway, but 
translated versions exist and are being used both in clinical practice and research 182. 
The ASRS version used in this study is the same that was used by the Expert 
Committees of Hyperkinetic Disorder/ADHD. It was originally translated and re-
translated (by an English-native employee of the Norwegian Department of Health and 
Social Welfare) and has later been evaluated by 4 experienced psychiatrists from our 
project group. The MDQ has been translated by a Norwegian psychiatrist (P. 
Bergsholm) and retranslated by an English-native psychologist, and is currently being 
used in clinical practice in Norway. The Norwegian WURS version has been used in 
earlier publications 182.  
In addition, the patients answered 31 questions concerning sociodemographic factors 
including educational and occupational level, past and present medical treatment and 
lifetime history of comorbid disorders. They were also asked about the presence of 
ADHD and comorbid disorders in first degree family members. All patients were 
asked to give a form to their doctor (mainly psychiatrists) with questions regarding 
diagnosis and medical treatment. These questionnaires were specifically designed for 




To assess the self-reported comorbidity on the questionnaire, a randomly selected 
subsample of patients living in the Bergen area (n=50, Paper II) was invited to a 
clinical interview. The interview took place at the out-patient section at the 
Department of Biological and Medical Psychology at the University of Bergen. The 
interview was based on the semi-structured module based Mini International 
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Neuropsychiatric Interview, the Plus version (M.I.N.I.-Plus) 183. The M.I.N.I.-Plus 
assesses general psychopathology in adults by covering main axis 1-diagnoses 
according to both DSM-IV and ICD-10. Patients and controls were interviewed in a 
random sequence as part of the main project with the interviewers being blinded to the 
subjects’ diagnostic status and self-report results. Two experienced psychiatrists 
performed the interviews (AH and MD, Paper II). After an initial phase of observing 
each other’s interview directly behind mirroring windows, video-recordings of the 
interviews were performed when feasible. However, complete inter-rating measures 




As part of the main project, a blood or saliva sample was obtained from all participants 
(in Papers I, II and IV) after informed consent. DNA from saliva was extracted using 
the Oragene TM DNA Self-Collection Kit, and by standard methods from blood. 
Sequencing of the all exons and intron-exon regions of TPH1 (and TPH2) was 
performed for 457 (459) patients and 187 (179) controls to identify mutations (Paper 
IV). Further genotyping targeting the found mutations was performed for 86 (97) 
family members of ADHD patients. Protein expression in E. Coli and Human 
Embryonic Kidney (HEK) cells, and analyses of TPH1 mutants, were then performed 




Data were initially analysed to describe and compare frequencies and prevalence of 
different variables, using contingency tables (Chi-square tests, Fisher’s Exact tests) for 
categorical variables and independent sample tests (Student T-tests) for non-
categorical variables. Regression analyses (logistic and linear) were then performed to 
explore possible effects of different variables on defined outcome measures. A two-
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tailed significance level of .05 was chosen for statistical significance. Odds ratios (OR) 
and relative risks (RR) were expressed with their corresponding 95 % confidence 
intervals (CI). 
The statistical analyses were mainly performed using SPSS (Statistical Package for the 
Social Sciences, SPSS Inc, Chicago, IL, USA) version 14.01 (Paper I), version 15.01 
(Papers II and IV) and PASW (Predictive Analytics Software, former SPSS) version 
18.0 (Paper III). In addition, STATA (STATA Intercooled release 9 (Stata Statistical 
Software: Release 9, 2005, College Statin, TX: StataCorp LP)) was used for RR 




An informed consent based on detailed written information about the project was 
obtained from all the participants included in Papers I, II and IV. All participants 
received NOK 250, - (~40$) upon return of questionnaires and spit or blood samples, 
and an additional NOK 500, - (~80$) if interviewed. Participants were not informed 
about results of individual genetic analyses. In the epidemiological study in Paper III 
included patients had provided a written, general consent that data from their records 
could be used in later research projects. Because the data in Paper III were treated 
anonymously, no further consent was required. The study was approved by the 
Regional Research Ethical Committee of Western Norway (IRB # 3 (FWA 00009490, 
IRB00001872), the Norwegian Directorate of Health and Social Services and the 






Paper I is a clinical case-control study assessing occupational outcome among adults 
with ADHD. Clinically diagnosed ADHD patients (n = 414) and a population-based 
control group (n = 359) responded to questionnaires rating past and present symptoms 
of ADHD, comorbid conditions, treatment history and work status. Twenty-four 
percent of the patients reported being in work, compared to 79 % of the controls. 
Logistic regression analyses were performed to assess predictors of being out of work 
among the adult ADHD patients. We found that the combined subtype of ADHD, 
substance abuse, and a reported history of depression/anxiety were correlated to being 
out of work. Medical treatment, current or past, was positively correlated to being in 
work. Being diagnosed and treated with central stimulants during childhood was the 
strongest predictor for being in work as an adult (OR 3.2, p = 0.014), independently of 
psychiatric comorbidity, substance abuse and current treatment. 
 
Paper II 
Paper II is a clinical case-control study investigating the relationship between ADHD 
and Bipolar spectrum disorders (BSD). Clinically diagnosed ADHD patients (n = 510) 
and a population-based control group (n = 417) responded to questionnaires rating 
symptoms of ADHD, psychiatric comorbidity, sociodemographic data, and a screening 
questionnaire for BSD, the Mood Disorder Questionnaire (MDQ). A subsample of the 
patients was interviewed with a semi-structured interview (M.I.N.I Plus) to assess 
correlations between self-reported and interview based psychiatric diagnoses. We 
found that 50.6 % of the ADHD patients screened positive for BSD based on the 
questionnaire (MDQ), compared to 8.3 % of the controls. In comparison, the 
prevalence of BSD according to the DSM-IV based interview was 32 %. In the total 
study sample (n = 927), an ADHD diagnosis was the strongest predictor for screening 
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positive on the MDQ (OR = 5.0, p<0.001), but the correlation between dimensional 
symptom levels of ADHD and of BSD was strongest in the control group. Patients 
screening positive for a BSD had significantly more drug problems, higher ADHD 
symptom scores and lower educational and occupational levels. The findings illustrate 
the close relationship between some symptoms of BSD and ADHD in adults. 
 
Paper III  
Paper III is an epidemiological, population-based study of pre- and perinatal risk 
factors in ADHD. It is the largest study on pregnancy- and birth complications in 
ADHD ever performed, and the only on adults with ADHD so far. A patient cohort 
consisting of all adult ADHD patients approved for treatment with central stimulants 
in Norway between 1997 and 2005 and who were born after 1966 (2323 patients) was 
compared with the remaining of the Norwegian adult population born in the same time 
period, 1967-1987 (1.17 million controls) by data linkage with the Medical Birth 
Registry of Norway (MBRN). The associations between pregnancy- and birth 
complications and adult ADHD were calculated and adjusted for potential 
confounders. We found that preterm and extremely preterm births (<37 and <28 weeks 
of gestation) were associated with 1.3- and 5.0-fold increased risks of developing 
persistent ADHD, respectively. Similarly, birth weights <2500 g and <1500 g were 
associated with 1.5- and 2.1-fold increased risks, and 5 minutes Apgar scores<4 and 
<7 with 2.8-and 1.5-fold increased risks of persistent ADHD. We also found an 
association between maternal epilepsy (RR=1.7) and offspring oral cleft (RR=2.8) and 
ADHD in the adult offspring.  
 
Paper IV 
Paper IV is a translational study investigating the long-term effects of an impaired 
serotonin synthesis on the developing human brain. We studied the effects of missense 
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and nonsense mutations affecting tryptophan hydroxylase (TPH) enzymes responsible 
for serotonin production in maternal reproductive tissues (TPH1) and the brain 
(TPH2), respectively. Sequencing of the entire TPH1 and TPH2 genes in 646 
Norwegian adults (ADHD patients, their relatives and control persons) identified 7 
different TPH1 coding variants in a total of 38 persons. Functional studies showed that 
6 of the variants had significantly decreased enzyme activity or stability in vitro 
compared to wild type TPH1. Subsequent family based analysis revealed that 
individuals born to mothers with TPH1 mutations reported 1.5- 2.5 times higher 
ADHD scores and related symptoms during childhood and as adults than controls (p< 
10-6), or individuals with fathers with the corresponding TPH1 mutations (p<0.001). 
This effect was independent of the children’s own TPH genotypes, indicating that 
maternal serotonin production has profound long-term behavioural effects on their 
offspring. The study illustrates a novel approach of investigation of the consequences 





The patient and control samples  
 
A main strength of the present study is the large sample size of ADHD patients and 
controls and the fact that they were recruited from all parts of the country. In the 
epidemiological study (Paper III) we had access to a national cohort of adult ADHD 
patients; all adult patients found eligible for CS treatment for ADHD, and born after 
1966, were included. This patient sample is, as far as we know, unique in its kind. 
Likewise, the control sample in this study is a national cohort consisting of the rest of 
the population born in the same time period. As the MBRN was established as early as 
in 1967 and covers the whole population with compulsory notification, it currently 
(2010) includes birth data on close to the entire adult population from 18 to 43 years. 
This allowed us to link our patient sample to the targeted age group.  
Many different clinicians, who were not connected to the project, diagnosed the 
patients.  The possible heterogeneity of the diagnostic assessment was compensated by 
the evaluation by one of the three Expert Committees. The studied patients thus 
represent a population-based naturalistic clinical setting, which is important for the 
external validity of the results. In other case-control studies of adult ADHD, patients 
are often diagnosed and recruited from one or a few specialized centres. Also, more 
strict inclusion criteria are often used, for example excluding patients with comorbid 
psychiatric disorders or substance abuse. These patient samples may be more 
homogeneous and have higher internal validity (diagnostic reliability), but the study 
results may be less generalizable to other clinical settings, which typically are very 
heterogeneous when adult ADHD is concerned. 
However, the low awareness of adult ADHD and the relatively stringent referral 
system for treatment at the time, have probably excluded some affected individuals 
from being diagnosed, and hence displaced the relative distribution between cases and 
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controls in our population sample. This is confirmed by the low prevalence estimates 
of adult ADHD (< 0.2 %) in our sample compared to other population-based 
prevalence estimates. Caution is therefore still required before generalizing the results 
from Paper III to samples including self-referred adults with milder symptoms not 
requiring medical treatment for their ADHD.  
In the clinical studies (Papers I, II, IV), our aim of gathering a naturalistic nation-wide 
sample of patients was limited by the relative low response rate among patients invited 
to the study. This may have biased our sample. Because we did not have information 
available to directly compare responding and non-responding patients, we do not know 
the direction or magnitude of this possible bias. Compared to the statistics from the 
national cohort of ADHD patients from the Expert Committee Registry (184, Michael 
Lensing, personal communication), the patients willing to participate in our study were 
older (62 % versus 42 % over 30 years) and more often women (48 % versus 29 %). 
The nature of the disorder itself (poor sustained attention, disorganization and 
procrastination) may have affected the response rate of patients by reducing their 
ability to fill in and return the questionnaires. The most severely affected and 
dysfunctional patients could therefore be overrepresented in the non-responders group. 
In that case the effects related to the ADHD patients in this study would be 
underestimated. It may also be that patients with fewer symptoms and problems were 
less motivated to participate in the study than patients with more symptoms, in which 
case the effects would be overestimated. It remains difficult to compare this to other 
clinical studies, since response rates are often lacking in sample descriptions. 
Interestingly, the response rate among the controls in our study was very similar to that 
of the patients. The low response rate of the invited controls may be due to 
characteristics of our project. People could be less interested in ADHD compared to 
other disorders, such as cancer or cardiovascular disease, which may affect them later 
in life. Furthermore, people may have higher thresholds for participating in studies 






The clinical information on symptom profiles and comorbidity (Papers I, II, IV) was 
mainly based on self-report questionnaires. We did not have information about the 
time of diagnosis for each patient. We could therefore not assess how the time of 
diagnosis may have influenced the symptom severity reported at the time of inclusion 
into the study (information bias), or the interest in participating (selection bias). Most 
of the patients in our sample had been treated with CS, and most of them with good 
response. However, data on the course of treatment were too crude to allow for 
analyses on how the treatment affected ADHD symptoms. This may have biased our 
data towards lower current symptom scores (ASRS) among patients, and may thus 
explain the relatively large proportions of patients in our study with sub-threshold 
scores on the ASRS at inclusion. Furthermore, the retrospective nature of some of the 
questions entails the problem of recall bias. Inaccurate recall could result in lower or 
more negative scores, whereas biased recall due to attribution (e.g. increased relative 
awareness of ADHD-related symptoms in childhood after having been diagnosed with 
ADHD in adulthood) could yield higher or more positive scores among patients 
relative to controls. Data on childhood treatment was also based on self-report in this 
study (Paper I), but we expect that this information would be less influenced by recall 
bias. However, the finding that treatment in childhood is positively correlated to being 
in work as an adult should ideally be verified in long-term, prospective, controlled 
studies. Methodological challenges- both ethical and practical- complicate the 
feasibility of such studies. Therefore, more open-labelled, observational studies are 
needed to explore this important finding and other predictors for long-term outcome of 
treatment of childhood mental disorders 185. 
The questionnaires have not influenced the diagnostic status of patients, since the 
diagnosis of ADHD/Hyperkinetic disorder was required before inclusion and 
confirmed on a separate form by the patient’s doctor. Other lifetime diagnosed 
disorders were, however, reported by the participants themselves, by responding ‘yes’ 
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or ‘no’ to questions like: “Do you have, or have you ever had, bipolar disorder?“. The 
gold standard for diagnostic assessment of psychiatric disorders is the clinical 
interview performed by an experienced clinician, and psychiatric disorders should 
never be diagnosed exclusively by self-report questionnaires. Assessment by interview 
is, however, still influenced by the personal judgement of the clinician in the decision 
of whether symptoms and impairment criteria are fulfilled 186. Self-reported disorders 
and problems may be valuable in reflecting the patients’ problems as they would be 
encountered in a clinical setting. The prevalence of self-reported comorbid psychiatric 
disorders and problems in the present study were comparable (often higher), to other 
clinical samples of adults with ADHD 36,44,61,187. The trend towards higher prevalence 
rates found in our study may be due the less stringent nature of self-reported 
diagnoses, or it may be due to a selection bias of our patients towards a more severely 
affected and /or less homogeneously defined sample. The self-report findings were 
however satisfactorily correlated to standard blinded diagnostic assessment in the 
interviewed subsample of patients (Paper II).  
 
Registry based measures  
In the epidemiological study (Paper III), data were extracted from population-based 
registries, with the Medical Birth Registry of Norway as the main source. Based on 
compulsory notification, this registry has collected information on all births, live and 
still, from 16 weeks’ gestation since 1967. A standardized notification form collects 
data on demographic variables, maternal health before and during pregnancy, 
complications during pregnancy and delivery, and pregnancy outcomes which include 
vital status of the newborn and congenital anomalies (See Appendix). The midwife 
and/or the physician attending the birth are responsible for completing the notification 
form.  
In Norway, all live births are also notified to the Directorate of taxes in a parallel civil 
system for registration of births. The national identification number of the newborn is 
generated and a new record is established in the Central Population Registry. All 
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records of the MBRN are routinely matched to those of the Central Population 
Registry, with mutual updating of files. Births in the Central Population Registry that 
are not notified to the MBRN are actively sought from delivery units, ensuring 
complete medical notification of all live born infants in the country. Selection bias of 
controls is therefore not a likely problem in this study (Paper III).  
The quality of the different variables of interest in this study varied. Birth weight is 
known to have good quality with little missing data (0.2 % in the inclusion period of 
the present study, K.K. Melve, personal communication). Gestational age was based 
on the mother’s reported last menstrual period, and is known to be less accurate. 
Ultrasound based gestational age is not reported in the MBRN before 1998. Due to the 
uncertainty of menstrual dates, we validated gestational age by calculating birth weight 
Z-scores for each gestational week 188. Births with Z-scores greater than 4.0 were 
excluded when analysing gestational age due to the misclassification. In the time 
period of this study, 5.3% of the births in the MBRN had missing values for 
gestational age, and 0.4% was misclassified.  
Information about Apgar scores has not yet been formally validated in the MBRN. 
They are available only from 1978, and could therefore not be studied for the whole 
sample. Most of our patients were, however, born in the latest part of the studied time-
period, and, hence included in the analyses on Apgar scores. Preliminary validation 
data on maternal epilepsy has so far shown satisfactory results (personal 
communication, I. Borthen). Whereas certain anomalies, such as heart defects, were 
underreported in the first time period of the MBRN, oral clefts have shown satisfactory 
ascertainment during the entire Registry period 189.  
Differential information bias between cases and controls may have occurred for those 
variables that are self-reported. For example, reports of menstrual dates by mothers of 
ADHD patients were generally more uncertain than for other mothers. Although it was 
not possible to verify the presence and direction of these potential information biases, 
we believe that, in general, they have most likely lead to underestimation of effects. 
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Association does not necessarily imply causality. Unmeasured and unknown factors 
may be associated to both the exposure and outcome variables in a way that would 
alter the found association if they were accounted for in the analyses. The roles of 
confounders relevant for the present study are mentioned in the Discussion of the main 
findings.  
 
Translational research - the value of combining different 
methodological approaches  
 
Large scale epidemiological studies are invaluable in providing evidence for 
associations and generating new hypotheses about risk factors for diseases. Other 
approaches like experimental animal studies, or functional molecular studies will often 
be necessary to elucidate pathogenetic mechanisms and the exact relation between 
putative risk factors and disease. However, as research methodologies evolve and 
become more specialized, it becomes increasingly challenging to communicate across 
disciplines. An overriding aim of the main project “ADHD in adults: from clinical 
characterization to molecular mechanism” was to apply a multi-disciplinary approach, 
i.e. combining people and their competences from different research areas, in the 
common focus of investigating clinical and pathophysiological aspects of adult 
ADHD.  
Despite massive efforts and rapid advances in technologies, the search for 
susceptibility genes for ADHD- and most other complex trait disorders- has so far not 
succeeded in explaining the bulk of observed heritability of the disorder (see 
Introduction). This “missing heritability”, and new approaches to uncover the 
underlying genetic architecture of complex diseases, is presently being hotly debated 
190
.  Nearly all published molecular genetic association studies on mental disorders are 
based on studies of common genetic markers, most of them with no apparent 
functional role; i.e. they rely on indirect associations between test markers and an 
unknown disease variant in its chromosomal vicinity. It has recently been proposed 
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that the accumulated effects of many different rare variants may confer a stronger risk 
to common, complex trait disorders 191,192. These rare variants may be difficult to 
detect, but when detected, they may be more informative in establishing a plausible 
causal association between genetic variants and impaired function related to the 
disorder. Furthermore, most genetic studies of psychiatric disorders focus on a single 
diagnosis or a limited number of symptoms, although it becomes increasingly 
recognized that susceptibility genes may have more general effects on brain function 
and be involved in different clinical syndromes. Finally, and importantly, the typical 
mode of inheritance investigated in genetic studies, i.e. how DNA variants segregate 
with phenotypes, may not be the only model accounting for disease susceptibility, but 
other models of disease susceptibility and transmission are generally not accounted for 
in genetic studies.  
Our study on the effects of maternal serotonin biosynthetic capacity and offspring 
behaviour (Paper IV) is unusual in many aspects, and illustrates an alternative 
approach to identify susceptibility genes, and pathomechanisms. Here we attempted to 
detect and functionally characterize all gene variants, which could have a direct effect 
on the protein level (i.e. of TPH). We thus studied many different mutations within the 
gene, with individual allele frequencies of approximately 0.1 %, most of which had an 
impact on the enzyme function using in vitro assays. In the phenotype approach, we 
collected information on various symptoms and problems, including dimensional 
measures on both ADHD and mood disorders. This allowed us to detect possible 
effects on brain development that were not limited to specific diagnostic entities. 
Finally, the main model examined in Paper IV was the transmission of a trait based on 
maternal genotype irrespective of the individual’s (offspring’s) own genotype. 
Although transgenerational effects on behaviour have been robustly demonstrated in 
animal models, molecular studies in human mental disorders have been sparse. Parent-
of-origin effects have, however, recently been highlighted as interesting approaches to 
pursue in order to reveal the genetic architecture of complex disorders 193. 
Together, the integration of clinical, genetic and molecular approaches in Paper IV, 
allowed us to formulate specific pathophysiological hypotheses that have hardly been 
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addressed in previous studies. However, considering its moderate sample size and still 
limited availability of clinical data, the study also illustrates some of the challenges of 
human behavioural genetics. 
The different methods and sample selections used across the papers in this thesis also 
give an advantage in elucidating the posed research questions. For example, in the 
investigation of pre- and perinatal risk factors’ role in ADHD, Paper III provides 
evidence of an association between disturbed foetal development and ADHD. The data 
does, however, not allow causal conclusions to be made about pathogenetic 
mechanisms 194. Paper IV indicates that one such mechanism could be mediated by 
impaired serotonin production in the early intrauterine environment 195. In the 
investigation of the relation between ADHD and other psychiatric symptoms and 
problems, the results in Paper II showed that the majority of our adult ADHD patients 
had co-existent affective symptoms and that the combination of ADHD symptoms and 
a high load of affective symptoms increased the risk of reported drug problems and 
other impairment (Paper I). In Paper IV, we found that reduced serotonin production in 
embryonic development may be a causal factor for this phenotype, since symptoms of 
ADHD, bipolar disorder and impulsive drug related behaviour were all increased in 
offspring to mothers with TPH1 mutations. Together, and by different means, these 
studies thus contribute to more coherent knowledge about a clinically important group 
of adult ADHD patients. 
 
Discussion of the main findings 
Functional impairment in adult ADHD 
 
The ongoing debate about ADHD either being a distinct disorder or just a normal 
variant of human behaviour is partly due to the non-specificity of symptoms of 
ADHD, in which most people will recognize themselves from time to time. The 
threshold for getting a diagnosis of ADHD is, however, dependent on the chronicity of 
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symptoms over time and the impairment caused by these symptoms in several 
important aspects of life, such as school, work, interpersonal relations etc. We found 
that only 24 % of the adults with ADHD in our study (mean age 34 years) were 
employed at the time of inclusion in the study. About half of the patients were 
receiving a disability pension or were under rehabilitation. Although ADHD is known 
to be associated with lower socio-economic status and educational level than controls, 
the proportion being out of work was surprisingly high compared to results from other 
(few) existing studies on the topic 16. In their follow-up study of hyperactive boys 
(average 7 years), Manuzza et al. found that as much as 90 % of the 85 probands were 
gainfully employed as adults (average 24 years) 196. In a large cross-sectional study of 
clinically referred adults, 73 % of adults diagnosed with ADHD were currently 
employed, not differing statistically from control samples 16. There may be several 
reasons for this. First, as discussed earlier, the patients in our study may represent a 
more severely affected group compared to other samples of adults with ADHD. 
Indeed, the patients recruited to the present study, i.e. representing the period of the 
mandatory referral to the expert committees, were, as a group, less often in work than 
patients recruited later (after 2007), both in our material (24 % versus 41%), and  as 
confirmed by other studies 61. Second, national differences in societal structure may 
account for some of the difference. The welfare system in Norway is quite developed 
and may provide for people who in other countries would be engaged in some kind of 
work although struggling, underachieving or not functioning properly, for example 
frequently changing jobs. 
The combined subtype of ADHD was associated with lower occupational outcome in 
our study. This group also had higher frequencies of reported alcohol and drug 
problems, comorbid affective disorders and treatment for other psychiatric disorders. 
This finding is consistent with other studies reporting that the combined subtype is 
associated with the poorest outcome among adults with ADHD 197,198. 
The finding that treatment, particularly treatment in childhood, was strongly associated 
with an increased probability of being in work in adulthood (Paper I) is an important 
finding that has not been clearly shown before. Follow-up studies of children with 
ADHD have rather found that treatment was associated with a more negative outcome, 
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although this was probably due to the confounding effect of increased symptom 
severity in children who received treatment 169. It has, however, been shown that 
treatment with CS may be protective against later substance abuse 47, which is in line 
with our findings. Although educational and occupational levels were highly 
correlated in our study, treatment in childhood did not seem to significantly affect the 
educational level attained. Symptom severity in childhood was the main risk factor of 
having the lowest level of education. This may be because adults with ADHD who 
were not recognized in childhood have been able to compensate their lower 
functioning until the demands of self-organizing are increased, or the external 
supporting structure decreased, as discussed earlier.  
 
ADHD and bipolar disorder- comorbidity or shared phenotypes? 
 
Comorbidity simply refers to the presence of two or more disorders occurring together. 
In somatic medicine, comorbidity usually refers to two or more distinct diseases (i.e. 
clinical entities with a known etiology or pathogenesis) being present together at the 
same time 199. In psychiatry, where the term disorder is used (i.e. clinical entities 
without a known etiology or pathogenesis), the nature of this co-occurrence may, 
however, range from independent disorders occurring together by chance, to co-
occurrence of disorders sharing some common or correlated underlying etiology, or it 
may simply represent an artefact of overlapping phenotypes 200,201. Disorders 
succeeding each other in time, i.e. lifetime comorbidity, may include situations in 
which the presence of one disorder is a risk factor for the other, or the two disorders 
may represent different developmental expressions of a common underlying 
vulnerability 202.  
The relationship between ADHD and bipolar disorder is not fully understood. One 
reason why this relation is difficult to investigate is the lack of a uniform 
understanding of the two disorders’ phenotypes in a developmental perspective. 
Parallel to the case of ADHD in adults, criteria for bipolar disorder are not adapted to 
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the juvenile or childhood onset form of bipolar disorder. Another reason is that the 
core symptom of BD - mood dysregulation- is also part of the common adjuvant 
symptoms of ADHD (see Introduction). These symptoms may be distinguished 
quantitatively, i.e. by periodicity and duration of mood swings, and to some extent also 
qualitatively, i.e. irritability versus hot temper. Still, the clinician is given room in his 
or her interpretation and decision-making about whether the mood symptoms in this 
particular individual seem more bipolar-like or ADHD-like. We thus applied a 
commonly used screening tool for bipolar disorder (MDQ) in our study, without 
telling the participants what they were screened for. According to standard cut-offs for 
this questionnaire (MDQ-positive) half of our ADHD patients (50.6 %) screened 
positive for a BSD compared to 12 % reporting a known bipolar disorder in the same 
sample. Using a broader cut-off (MDQ7positive), more than 70 % of the patients 
screened positive on the MDQ. This gap between the presence of symptoms of BD and 
of diagnosed BD illustrates two important points: First, symptoms of bipolar disorder 
are highly frequent in adults with ADHD, while a diagnosis of BD not necessarily is. 
Second, the prevalence of BD diagnosis is highly dependent on the subtype or 
definition of BD being used. Although this may seem logical, the clinical 
consequences may be difficult to follow and may depend on the clinician’s viewpoint 
or experience in diagnosing the two disorders. A positive screen on a questionnaire 
should never be sufficient to make a diagnosis, but should be confirmed or 
disapproved by a comprehensive patient interview. As ADHD is not included in 
standard interviews of psychopathology for adults, a diagnosis of ADHD, which we 
have shown is a strong predictor for screening positively for BD, will not be confirmed 
unless it is thought of a priori by the clinician. The large variations in prescription of 
central stimulants between different counties in Norway (data from the Norwegian 
prescription database available from: http://www.reseptregisteret.no/) and between 
different states in the USA 203 indicate that traditions and attitudes in diagnosing and 
treating ADHD still may play a role in defining the disorder.  
Comorbidity studies have found very varying prevalence of BD among adult ADHD 
patients, from rates around 1 %, i.e. similar to the general population 16 to elevated 
rates ranging from 5 to 47 % (for review see Wingo et al. 2007 204). The prevalence of 
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BD in our interviewed sample varied from 8 to 32 % according to the definition of BD 
used, and this illustrates some of the challenges in assessing the relationship between 
the two disorders. ADHD does not seem to be particularly difficult to distinguish from 
the clearly episodic BD1. However, the recent widening of the bipolar spectrum 
includes more chronic clinical pictures of (brief) recurrent depressions, alternating or 
co-occurring with elevated or dysphoric mood swings, and often complicated by 
substance abuse. It is this bipolar spectrum beyond BD1 that really challenges the 
distinction between ADHD and BD, and also some personality disorders, in particular 
borderline personality disorder (see Introduction and Paper II) 205,206. Interestingly, 
recent studies have shown that a positive score on the MDQ frequently is correlated to 
these other psychiatric disorders also in the absence of a diagnosed BD 207,208.  
Another issue emerging from the findings in Paper II, is the question whether the 
bipolar-like symptoms should be considered an inherent part of the ADHD syndrome, 
a distinct subtype of ADHD, or co-occurring symptoms qualitatively distinct from core 
symptoms of ADHD. The fact that most patients had a high load of symptoms of BD 
without having a BD diagnosis indicates that the measured bipolar symptoms are an 
inherent part of the ADHD syndrome and not an artefact of misdiagnosed BD. Also, 
the presence of bipolar symptoms is clinically important since it is associated with 
more impairment than ADHD without such symptoms. This is in line with other 
studies showing that emotional symptoms and problems affect the outcome of ADHD 
negatively (more behavioural problems, substance abuse, less capable of working). It 
is currently being debated whether emotional lability should be included in the formal 
diagnostic criteria of ADHD. Because it is the majority, and not a minority of patients 
that report such symptoms, we think it is appropriate to consider these symptoms as an 







The role of pre- and perinatal factors in the etiology of ADHD 
 
Paper III and IV of this thesis provide evidence- by different means- that pregnancy 
and birth related factors are associated with the development of ADHD and related 
symptoms and behaviour later in life.  
The epidemiological study (Paper III) shows an association between various 
pregnancy and foetal factors (low birth weight, growth restriction, preterm birth, low 
Apgar scores, maternal epilepsy in pregnancy) and ADHD in adults. Low birth weight 
(LBW), as well as other indirect measures of a suboptimal prenatal environment, are 
known to increase an individual’s risk for disease in later life 209,210. Although LBW 
has already been shown to be associated with ADHD in children 156,157, our study is the 
first to show such an association in adults with ADHD. This is important added 
knowledge to the discussion on developmental aspects of ADHD since it presently 
remains unclear whether ADHD persisting to adulthood is caused by the same factors 
as ADHD remitting in childhood or adolescence. Our findings that preterm birth is 
associated with ADHD in adulthood extend findings from childhood studies 157. 
Further, the association with low Apgar scores support experimental and imaging 
studies suggesting reduced cerebral blood flow in foetal life (in particular to the basal 
ganglia) as a putative pathogenetic mechanism in ADHD 211,212.  
Systematic reports on maternal smoking are not available in the MBRN for births 
before 1987. We could therefore not adjust our results for maternal smoking. This 
clearly is a limitation in our study, considering the large amount of literature pointing 
to an association between smoking in pregnancy and ADHD 152,213. However, recent 
studies with innovative designs capable of separating genetic and environmental 
influences, question the nature of this relation, suggesting that it may not be causal, but 
genetically mediated 214,215. If this is the case, adjusting for maternal smoking would 
not necessarily alter our results. 
The associations in our sample between maternal epilepsy and ADHD, as well as 
between infant oral cleft and ADHD, are new findings. The epidemiological nature of 
the study only allows us to speculate about possible causal mechanisms underlying 
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these associations. Thus, maternal epilepsy may be linked to ADHD in the offspring 
through various pathways; direct effects of hypoxic states during epileptic seizures in 
pregnancy; a common genetic vulnerability for the two disorders as in the case of 
16p11.2 duplication 216; or direct (teratogenic) or indirect effects of anti-epileptic drugs 
on the foetus. The latter may possibly be mediated through low maternal folate status, 
which has recently been shown to be associated with behavioural outcomes in human 
offspring, presumably due to an effect on brain development 217.  
Likewise, the association found between infant oral cleft and ADHD may depend on 
common genetic or environmental risk factors affecting the development of both these 
apparently different phenotypes. The use of folic acid in pregnancy has recently been 
shown to be associated with oral cleft in the offspring 218. Our epidemiological data 
point to foetal growth restriction as a risk factor for ADHD, independent of LBW and 
preterm birth. Foetal growth restriction may be caused by several factors, both 
maternal (placental dysfunction, poor nutrition, psychosocial stress, smoking in 
pregnancy, or altered hormonal status) and infant related (congenital malformations or 
genetic syndromes). Animal studies have indicated that serotonin plays an important 
role in embryonic morphogenesis by regulating developmental processes even before 
it starts acting as a neurotransmitter 219,220, including effects on the formation of 
craniofacial and palatal structures 221,222. Altered serotonin levels in intrauterine life 
could thus be linked to both neurobehavioural symptoms as in ADHD, and to oral 
cleft.  
Furthermore, studies of TPH1 knock-out mice have shown that normal embryonic 
development in mice is more dependent on maternal serotonin production than that of 
the embryo itself 121. Paper IV represents a first attempt to replicate and explore the 
potential relevance of this latter finding in a sample of humans. Although it was not 
possible to study a real knock-out-effect (since all our TPH1 mutations were 
heterozygous), functional studies showed reduced enzyme function in vitro for nearly 
all the studied TPH1 mutations, indicating that serotonin production is impaired in 
mutation carriers. We found higher levels of ADHD symptoms (both inattentive and 
hyperactive/impulsive symptoms), mood symptoms, and impulsive drug related 
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behaviour in adult offspring of mothers with TPH1 mutations, compared to offspring 
of fathers with TPH1 mutations, and a control population without mutation, 
independent of the offspring’s genotype. Our findings thus confirm those from the 
mice studies by Côté et al. concerning the importance of maternal serotonin production 
for development.  
Clinical implications of these findings should include increased awareness regarding 
the use of agents that alter serotonin levels during pregnancy. At present, TPH-
blocking agents are being developed for use in gastrointestinal disorders like irritable 
bowel syndrome 223, which is frequently reported among young women 224. In view of 
our findings, caution should be made before administering such agents to pregnant 
women.  
Selective serotonin reuptake inhibitors (SSRI) are widely used antidepressants, also 
among pregnant women, although concern is increasingly raised regarding their 
possible adverse effects on the foetus 225. These effects includes congenital heart 
defects 226, pulmonary hypertension, foetal growth restriction 195, preterm birth 227,228, 
as well as neonatal withdrawal syndrome, and increased need for intensive care in the 
newborn child. Animal studies have shown that exposure to SSRI in utero may 
increase depression/anxiety-like traits in the adult offspring, i.e. the “SSRI paradox” 
229
. Possible long-term effects of prenatal exposure to SSRIs on human 
neurodevelopment are, however, still unclear 230, but it has been suggested that 
deviations in either direction from optimal serotonin levels, during critical periods of 
developmental, may produce dramatic and long-lasting alterations in the organism 231.  
Recent studies have shown that impaired serotonin production affects insulin-
production in pregnant mice, suggesting a possible risk factor for gestational diabetes 
232
.  Interestingly, although the difference did not reach statistically significance, 
maternal diabetes was more frequent among ADHD mothers than among control 
mothers in our epidemiological study (Paper III). Together, findings from this work 
(Paper III and Paper IV) emphasize that factors influencing the intrauterine 
environment, with impaired serotonin production as one proposed pathway, may have 
  
62 






- Adults with ADHD had lower educational levels and far lower participation in 
occupational life compared to the general population. 
- Among adults with ADHD, a diagnosis and treatment of ADHD in childhood 
was associated with an increased probability of being in work in adulthood. 
- ADHD was often comorbid and overlapping with the broadly defined bipolar 
spectrum disorders.  
- Emotional lability was an important and impairing part of the symptom profile 
in a majority of adults with ADHD, and was associated with more severe 
ADHD symptoms, more alcohol and substance use, and lower occupational 
functioning. 
- Unfavourable conditions in pregnancy and delivery, expressed by low birth 
weight, preterm birth, growth restriction and low Apgar scores were associated 
with increased risk of developing ADHD persisting to adult life. 
- Impaired maternal serotonin production was associated with an increased risk of 
ADHD like symptoms and behaviour in adult offspring, independently of 






A main issue ensuing from the work of this thesis is the importance of exploring 
boundaries between psychiatric diagnoses and the value of using cross-diagnostic 
approaches when studying putative risk factors of diseases. The developmental 
perspective of psychiatric disorders is also a topical issue that should be emphasized in 
future research. 
The close relationship between ADHD and bipolar symptoms demonstrated in Paper II 
warrants further research. Emotional dysregulation is increasingly recognized as an 
inherent and impairing feature of ADHD. These problems are often interpreted as 
being qualitatively different from the mood swings typical of bipolar disorder, but- as 
shown by our work- this difference may be less clear in the interface between the 
broadly defined bipolar spectrum disorders and ADHD in adults, or- as shown by 
others- between juvenile bipolar disorder and ADHD in children 57. A follow-up of the 
findings of Paper II should include assessment of past and current ADHD symptoms in 
future studies of bipolar patients, in particular BD II and beyond, to further explore the 
interface between these diagnoses. Developmental aspects of the relation between 
ADHD and bipolar disorder should ideally be addressed in long-term, prospective 
studies of children followed to adulthood.  
As long as the clinical interview remains the gold standard of ‘well-defined’ 
psychiatric diagnoses, there will continue to be disagreement about the validity of 
‘newer’ diagnoses, as well as subthreshold and borderline cases. These ‘well-defined’ 
diagnostic categories may also actually impede research aiming at understanding the 
pathogenesis of psychiatric disorders. A dimensional approach to psychiatric 
symptoms across formal diagnostic entities may be more fruitful in reflecting the full 
spectrum of disorders and yielding information of underlying risk factors, which do 
not necessarily follow the boundaries of current diagnostic categories. This is 
illustrated by the findings in Paper IV, where impaired maternal serotonin production 
seems to be associated to a phenotype including cognitive deficits, mood symptoms 
  
65 
and impulsive behaviour, rather than to a formal diagnosis of ADHD. As attempted in 
Paper IV, in the search of genetic causes for ADHD and other complex disorders, there 
should be more emphasis on functional studies of putative genes of interest, in order to 
move from associative to causative relationships and thus to advance the 
understanding of the etiology of the disorder.  
In our epidemiological study on pre- and perinatal risk factors (Paper III) we did not 
have access to symptom profiles and comorbid diagnoses for the whole patient cohort 
that was studied. We have, however, initiated a study on our clinically recruited patient 
sample, to investigate if the associations found with e.g. low birth weight and maternal 
epilepsy are specific to subgroups of ADHD patients, e.g. the predominantly 
inattentive subtype. This may guide us towards more specific pathogenetic 
explanations between risk factors and disease, and eventually influence psychiatric 
diagnostic classification towards a more etiologically based understanding. We are 
also planning an epidemiological study within the Norwegian Medical Birth Registry 
comparing a national cohort of children versus adults with ADHD to investigate more 
directly possible differences in pre- and perinatal risk factors for ADHD across the 
life-span.  
Finally, and related to Paper I, I would like to emphasize the importance of assessing 
the functional impairment of disorders, and of studying how treatment and other 
interventions influence functional rather than pure symptomatic aspects. Obviously, 
more long-term studies from naturalistic/observational settings are needed to assess the 
real efficiency- not only short-term effects- of treatment and the role of early 
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